United Therapeutics Licenses Arena’s Ralinepag for US$800 M Upfront

By Michelle Liu

Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)

Published: 24 Nov-2018

DOI: 10.3833/pdr.v2018.i11.2373     ISSN: 1756-7874

Section: Licensing



United Therapeutics has signed an agreement for the worldwide licence to develop, manufacture and commercialise Arena’s ralinepag for the treatment of pulmonary arterial hypertension (PAH)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details